Genmab’s Tivdak approved in Japan for advanced cervical cancer
Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat ...
The Pharma Letter2d
Genmab’s Tivdak approved in Japan
Danish cancer specialist Genmab today announced that the Japanese Ministry of Health, Labor and Welfare has approved Tivdak ...
Why Pfizer Is My Largest Healthcare Position
Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...
Colorectal Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...
Pfizer Is Trading As If It's 2009 Again
Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...
CARVYKTI Continued Performance Reflects Growing Confidence in CAR-T Therapies for Multiple Myeloma | DelveInsight
DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...
Pfizer Is Now a High-Yield Bargain Stock
Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?
Zacks Investment Research on MSN5d
Pfizer Is a Dirt-Cheap High-Yield Stock, But Is It a Buy?
Of late, pharmaceutical behemoth Pfizer Inc.’s PFE stock has struggled, but it remains a bargain with generous dividends. Its ...